INmune Bio partners with Quantum Computing Inc. to apply quantum optimization, AI in Alzheimer’s drug research

By Public Technologies
  • INmune Bio entered a collaboration with Quantum Computing to apply quantum computing, AI, and analytics to expand research on XPro1595.
  • Work will use QCi’s Dirac-3S quantum optimization machine with clinical and public datasets to identify new indications and biomarkers.
  • Partnership targets diseases with biology aligned to XPro’s selective inhibition of soluble TNF, aiming to prioritize candidates with higher success odds.
  • Stage 1 marks QCi’s first commercial pharma and biotech customer, with options for additional work as programs advance.
  • Teams will benchmark quantum optimization results against conventional statistical and machine-learning methods to assess where quantum adds value.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140845PRIMZONEFULLFEED9845312) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.